1.Facchinetti F, Tiseo M, Di Maio M, Graziano P, Bria E, Rossi G, Novello S. (2016) Tackling ALK in non-small cell lung cancer: the role of novel inhibitors.. Transl Lung Cancer Res, 5 (3):(301-21). [PMID:27413712]
2.Johnson TW, Richardson PF, Bailey S, Brooun A, Burke BJ, Collins MR, Cui JJ, Deal JG, Deng YL, Dinh D et al.. (2014) Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.. J Med Chem, 57 (11):(4720-44). [PMID:24819116]
3.Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L et al.. (2016) Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.. N Engl J Med, 374 (1):(54-61). [PMID:26698910]
4.Shipman L. (2016) Resistance: Crizotinib makes a comeback.. Nat Rev Cancer, 16 (2):(69). [PMID:26797648]
5.Zou HY, Li Q, Engstrom LD, West M, Appleman V, Wong KA, McTigue M, Deng YL, Liu W, Brooun A et al.. (2015) PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.. Proc Natl Acad Sci USA, 112 (11):(3493-8). [PMID:25733882]
6.Saha D, Kharbanda A, Yan W, Lakkaniga NR, Frett B, Li HY. (2020) The Exploration of Chirality for Improved Druggability within the Human Kinome.. J Med Chem, 63 (2):(441-469). [PMID:31550151]
Solution Calculators
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
F23251452